Drug | IC50 (μM) | Achievable concentrations in plasma (based on the literature) | |||||
---|---|---|---|---|---|---|---|
BD | DH82 | [plasma] (μM) | Species | Dose | Effect | Ref. | |
Dasatinib | 0.01 | 0.009 | 0.3 | dog | 3Â mg/kg | NOAEL | [72] |
Erlotinib | 3.2 | 4.3 | 6.9 | dog | 150Â mg | TD | [73] |
Gefitinib | 30.7 | 46.4 | 2.6 | dog | 100Â mg/kg | NOAEL | [74] |
Imatinib | 34 | 39.2 | 0.66 | dog | 10Â mg/kg | NOAEL | [75] |
Masitinib | 15.7 | 39.1 | 1.5 | dog | 10Â mg/kg | TD | [76] |
Nilotinib | 29.9 | 26.2 | 1.4 | dog | 20Â mg/kg | NOAEL | [77] |
Toceranib | 1.9 | 1.7 | 0.1 | dog | 3.25Â mg/kg | TD | [78] |
Sorafenib | 36.3 | 13.6 | 13.3 | human | 400Â mg | TD | [79] |
Sunitinib | 4.5 | 17.9 | 0.12 | human | 50Â mg | TD | [80] |
Tozasertib | 7.7 | 1.3 | 0.27 | human | 8Â mg/m2 | TD | [81] |
CCNU | 105 | 139.5 | 4.2 | human | 130Â mg/m2 | TD | [69] |
Cladribine a | 64 | 222 | 0.028 | human | 0.09Â mg/kg | TD | [82] |
Doxorubicin a | 0.09 | 0.41 | 1.13 | dog | 30Â mg/m2 | TD | [83] |